Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population

Patient Preference and Adherence

Volumn 10, Issue , 2015, Pages

  Dilla, Tatiana ^a   Lizan, Luís ^b   Paz, Silvia ^b   Garrido, Pilar ^c   Avendaño, Cristina ^d   Cruz Hernández, Juan J ^e   Espinosa, Javier ^f   Sacristán, José A ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b UNIVERSITAT JAUME I   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Ciudad Real General Hospital   (Spain)

Author keywords

Clinically meaningful outcomes; Cost; Cost effectiveness; Cost effectiveness threshold; ICER; Oncology; Spain

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; ONCOLOGIST; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SPAIN; TREATMENT OUTCOME;

EID: 84951310104     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S93760     Document Type: Article

References (34)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11. Lyon: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
2. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840-1850.
3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-1907.
4. Patel JD, Krilov L, Adams S, et al. Clinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2014;32:129-160.
5. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol. 2013;31:3600-3604.
6. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence (NICE); 2008.
7. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence? Health Aff (Millwood). 2000;19:92-109.
8. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16:334-343.
9. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25:667-677.
10. Ellis LM, Bernstein DS, Voest EE, et al. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277-1280.
11. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990;300:1458-1460.
12. Berry SR, Bell CM, Ubel PA, et al. Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28:4149-4153.
13. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood). 2010;29:196-202.
14. Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care. Isr J Health Policy Res. 2013;2:44.
15. Nadler E, Eckert B, Neumann P. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11:90-95.
16. Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v quality of life-enhancing treatments. Med Decis Making. 2011;31:380-385.
17. Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Aff (Millwood). 2012;31:709-717.
18. Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions. Value Health. 2013;16:842-847.
19. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349-356.
20. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ. 2009;338:b181.
21. Raftery J. Should NICE's threshold range for cost per QALY be raised? No. BMJ. 2009;338:b185.
22. Claxton K, Martin S, Soares M, et al. Methods for the Estimation of the NICE Cost Effectiveness Threshold. York: Centre for Health Economics; University of York; 2013:81.
23. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796-797.
24. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2012;102:82-88.
25. Camps-Herrero C, Paz-Ares L, Codes M, et al. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. Clin Transl Oncol. 2014;16:914-920.
26. Sacristán JA. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak. 2013;13:6.
27. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30:4249-4255.
28. Rocke DJ, Beumer HW, Taylor DH, Thomas S, Puscas L, Lee WT. Physician and patient and caregiver health attitudes and their effect on medicare resource allocation for patients with advanced cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(6):497-503.
29. Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008;188:26-28.
30. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008;11:771-783.
31. National Institute for Health and Clinical Excellence. Appraising Life-Extending, End of Life Treatments. London: NICE; 2009.
32. Moïse P, Fassler P. Estimating NICE's cost-effectiveness threshold for end-of-life cancer treatments [abstract]. Value Health. 2011;14:A173.
33. Lakdawalla DN, Jena AB, Doctor JN. Careful use of science to advance the debate on the UK cancer drugs fund. JAMA. 2014;311:25-26.
34. Marshall B, Cardon P, Poddar A, et al. Does sample size matter in qualitative research?: a review of qualitative interviews in is research. J Comput Inform Syst. 2013;54(1):11-22.